Rare disease and gene therapy stocks, battered in recent months by clinical and commercial setbacks, will likely benefit from the sudden departure this past week of Vinayak (Vinay) Prasad, MD, as ...

Vinay Prasad's interim replacement has concerns about same drug that drove him out. NIH director says employee critics ...